• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pituitary tumors in 2010: a new therapeutic era for pituitary tumors.

作者信息

Gueorguiev Maria, Grossman Ashley B

机构信息

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, London EC1M 6BQ, UK.

出版信息

Nat Rev Endocrinol. 2011 Feb;7(2):71-3. doi: 10.1038/nrendo.2010.233.

DOI:10.1038/nrendo.2010.233
PMID:21263436
Abstract
摘要

相似文献

1
Pituitary tumors in 2010: a new therapeutic era for pituitary tumors.2010年的垂体瘤：垂体瘤治疗的新时代。
Nat Rev Endocrinol. 2011 Feb;7(2):71-3. doi: 10.1038/nrendo.2010.233.
2
Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".关于“激素分泌性垂体瘤的非手术治疗”的评论
J Clin Neurosci. 2010 Sep;17(9):1220-1. doi: 10.1016/j.jocn.2010.01.014. Epub 2010 Jun 8.
3
Treatment of pituitary tumors: somatostatin.垂体肿瘤的治疗：生长抑素。
Endocrine. 2005 Oct;28(1):93-100. doi: 10.1385/ENDO:28:1:093.
4
Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.帕西瑞肽，一种多生长抑素受体配体，对治疗垂体和神经内分泌肿瘤具有潜在疗效。
Drugs Today (Barc). 2013 Feb;49(2):89-103. doi: 10.1358/dot.2013.49.2.1915142.
5
Multimodality treatment of pituitary adenomas.垂体腺瘤的多模态治疗
Clin Neurosurg. 2005;52:234-42.
6
Somatostatin and somatostatin receptors in Cushing's disease.库欣病中的生长抑素和生长抑素受体
Mol Cell Endocrinol. 2008 May 14;286(1-2):199-205. doi: 10.1016/j.mce.2007.10.015. Epub 2007 Nov 22.
7
The pharmacological aspects of the treatment of acromegaly.肢端肥大症治疗的药理学方面。
Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68. doi: 10.1006/phrs.1996.0095.
8
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.长效兰瑞肽和奥曲肽长效注射剂对既往未经治疗的肢端肥大症患者肿瘤缩小及生长激素分泌过多的长期影响。
Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71. doi: 10.1046/j.0300-0664.2001.01438.x.
9
The role of somatostatin analogs in Cushing's disease.生长抑素类似物在库欣病中的作用。
Pituitary. 2004;7(4):257-64. doi: 10.1007/s11102-005-1404-x.
10
Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.新型生长抑素配体的临床前和临床经验：优势、劣势与新前景。
J Endocrinol Invest. 2005;28(11 Suppl International):36-42.

引用本文的文献

1
The nomogram for predicting nasal bleeding after endoscopic transsphenoidal resection of pituitary adenomas: a retrospective study.预测垂体腺瘤经鼻内镜经蝶窦切除术后鼻出血的列线图：一项回顾性研究
Front Surg. 2024 Jul 19;11:1409298. doi: 10.3389/fsurg.2024.1409298. eCollection 2024.
2
Structural insights into somatostatin receptor 5 bound with cyclic peptides.与环状肽结合的生长抑素受体 5 的结构见解。
Acta Pharmacol Sin. 2024 Nov;45(11):2432-2440. doi: 10.1038/s41401-024-01314-8. Epub 2024 Jun 26.
3
Structural basis for activation of somatostatin receptor 5 by cyclic neuropeptide agonists.

本文引用的文献

1
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.替莫唑胺治疗侵袭性垂体瘤：临床疗效与 O(6)-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）启动子甲基化和表达的相关性。
J Clin Endocrinol Metab. 2010 Nov;95(11):E280-90. doi: 10.1210/jc.2010-0441. Epub 2010 Jul 28.
2
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.替莫唑胺治疗侵袭性垂体瘤和垂体腺癌：法国多中心经验。
J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644. Epub 2010 Jul 21.
3
神经肽激动剂激活生长抑素受体 5 的结构基础。
Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2321710121. doi: 10.1073/pnas.2321710121. Epub 2024 Jun 17.
4
SOX2 mediates crosstalk between Sonic Hedgehog and the Wnt/β-catenin signaling pathway to promote proliferation of pituitary adenoma cells.SOX2介导音猬因子与Wnt/β-连环蛋白信号通路之间的串扰，以促进垂体腺瘤细胞的增殖。
Oncol Lett. 2019 Jul;18(1):81-86. doi: 10.3892/ol.2019.10311. Epub 2019 May 3.
5
Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.采用基因芯片预测分析方法鉴定具有诊断价值的垂体腺瘤潜在生物标志物
J Mol Neurosci. 2019 Nov;69(3):399-410. doi: 10.1007/s12031-019-01369-x. Epub 2019 Jul 6.
6
Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.分泌型卷曲相关蛋白4在侵袭性垂体腺瘤中的低表达
Pituitary. 2015 Jun;18(3):335-42. doi: 10.1007/s11102-014-0579-4.
7
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.AIP 失活通过缺陷的 Gαi-cAMP 信号导致垂体肿瘤发生。
Oncogene. 2015 Feb 26;34(9):1174-84. doi: 10.1038/onc.2014.50. Epub 2014 Mar 24.
8
Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors.经典和非经典 Wnt 通路的组成部分在垂体肿瘤中没有异常表达。
PLoS One. 2013 Apr 26;8(4):e62424. doi: 10.1371/journal.pone.0062424. Print 2013.
9
Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics.侵袭性库欣综合征的治疗策略：从大腺瘤到异位。
J Oncol. 2012;2012:685213. doi: 10.1155/2012/685213. Epub 2012 Aug 9.
Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
帕西瑞肽单药治疗或联合卡麦角林及酮康唑治疗库欣病
N Engl J Med. 2010 May 13;362(19):1846-8. doi: 10.1056/NEJMc1000094.
4
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.帕瑞肽（SOM230）治疗肢端肥大症的疗效和安全性：一项随机、多中心、II 期临床试验。
J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21.
5
The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.多巴胺-生长抑素嵌合化合物 BIM-23A760 通过激活 ERK1/2 和 p38 通路对人无功能垂体瘤发挥抗增殖和细胞毒性作用。
Cancer Lett. 2010 Feb 28;288(2):170-6. doi: 10.1016/j.canlet.2009.06.034. Epub 2009 Jul 19.
6
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.侵袭性垂体肿瘤中O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）低表达与对替莫唑胺的反应
Clin Endocrinol (Oxf). 2009 Aug;71(2):226-33. doi: 10.1111/j.1365-2265.2008.03487.x. Epub 2008 Dec 3.
7
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.多受体配体生长抑素类似物帕瑞肽（SOM230）治疗垂体依赖性库欣病：一项多中心II期试验
J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28.
8
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.O6-甲基鸟嘌呤-DNA甲基转移酶免疫表达可预测垂体瘤对替莫唑胺治疗的反应性。
Acta Neuropathol. 2008 Feb;115(2):261-2. doi: 10.1007/s00401-007-0279-5. Epub 2007 Oct 10.